论文部分内容阅读
探讨多药耐药因子在肺癌中表达与共表达的相关性及其临床意义。方法:采用免疫组化SP技术检测52例肺癌患者病理组织中P-糖蛋白(P-gp)、多药耐药相关蛋白(MRP)、谷胱甘肽S转移酶Ⅱ(GST-Ⅱ)3种多药耐药因子的表达水平。结果:肺癌组织中P-gp、MRP、GST-Ⅱ阳性表达率分别为51.9%(27/52)、61.5%(32/52)和78.8%(41/52);耐药因子在不同病理类型、不同TNM分期和不同分化程度间表达差异无显著性(P>0.05);P-gp和MRP均阳性40.1%,P-gp和GST-Ⅱ均阳性44.2%,MRP和GST-Ⅱ均阳性50.0%,P-gp、MRP和GST-Ⅱ均阳性21.2%,其中P-gp与MRP间阳性表达率呈正相关关系(rs=0.632,P<0.01),P-gp与GST-Ⅱ间阳性表达率呈正相关关系(rs=0.521,P<0.01),MRP与GST-Ⅱ间阳性表达率呈正相关关系(rs=0.532,P<0.01)。结论:肺癌的多药耐药现象是由多个耐药因子共同参与作用的结果,肺癌多药耐药的发生与不同的病理组织类型、不同TNM分期、不同分化程度间无关联。
To investigate the correlation between multidrug resistance factor expression and co-expression in lung cancer and its clinical significance. Methods: The expressions of P-glycoprotein, MRP, GST-Ⅱ 3 in 52 lung cancer patients were detected by immunohistochemical SP method Multidrug resistance factor expression levels. Results: The positive rates of P-gp, MRP and GST-Ⅱ in lung cancer tissues were 51.9% (27/52), 61.5% (32/52) and 78.8% (41/52), respectively. (P> 0.05); P-gp and MRP were positive 40.1%, P-gp and GST-Ⅱ were 44.2% positive, MRP and GST-Ⅱ were positive 50.0 %, P-gp, MRP and GST-Ⅱ were positive 21.2%, P-gp and MRP positive expression rate was positively correlated (rs = 0.632, P <0.01), P-gp and GST-Ⅱ positive expression rate (Rs = 0.521, P <0.01). There was a positive correlation between MRP and GST-Ⅱ (rs = 0.532, P <0.01). Conclusion: The multidrug resistance in lung cancer is the result of multiple drug resistance factors. The multidrug resistance of lung cancer is not associated with different pathological types, different TNM stages and different degrees of differentiation.